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Pathogenetic mechanisms of hepatocellular carcinoma (HCC) are still unclear and new tools for diagnostic and therapeutic purposes
are ongoing. We have assessed whether squamous cell carcinoma antigen (SCCA), a serpin overexpressed in neoplastic cells of
epithelial origin, is also expressed in liver cancer. Squamous cell carcinoma antigen was evaluated by immunohistochemistry in 65
HCCs of different aetiology and in 20 normal livers. Proliferative activity was assessed using MIB-1 antibody. In 18 surgical samples,
tumour and nontumour liver tissue was available for SCCA cDNA amplification and sequencing. Squamous cell carcinoma antigen
was detected in 55 out of 65 (85%) tumour specimens, but in none of the 20 controls. In the majority of the cases, the positive signal
was found in the cytoplasm of more than 50% of the hepatocytes. Low or undetectable SCCA (scorep1) was associated to lower
MIB-1 labelling index, compared to cases with SCCA score X2 (mean7s.d.: 2%72.4 vs 7.5%710.3, Po0.05). Squamous cell
carcinoma antigen mRNA could be directly sequenced in 14 out of 18 liver tumours but in none of the corresponding nontumour
samples. From sequence alignment, a novel SCCA1 variant (G351 to A) was identified in five cases, while SCCA1 was revealed in six
cases and SCCA2 in three cases. In conclusion, SCCA variants are overexpressed in HCC, independently of tumour aetiology. A
novel SCCA1 variant has been identified in one third of liver tumours.
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Hepatocellular carcinoma (HCC) is one of the most important
sanitary problems over the world for its high prevalence and for its
poor prognosis. More than 250000 new cases per year are
diagnosed and mean 5-year survival is lower than 5% (El-Serag
and Mason, 1999). Several factors have been involved in the
development of liver cancer, some of them differing in various
geographic areas and explaining, at least in part, distinct
geographical incidence (Bruix et al, 2001). The most powerful
risk factor is the presence of liver cirrhosis. Among cirrhotic
Caucasian patients, chronic viral infection by HBV and HCV are
the most biologically relevant causes leading to this clinical
condition (Benvegnu ` et al, 1994). However, pathogenetic mechan-
isms of neoplastic transformation are still unclear; several growth
factors and tumour suppressor genes (Collier et al, 1993; Naka et al,
1998; Abou-Shady et al, 1999) have been involved but insufficient
data have been generated to date. cDNA microarray analyses for
gene expression profiling and potential identification of target
genes for diagnostic or therapeutic purposes are ongoing (Shirota
et al, 2001; Takeo et al, 2001; Xu et al, 2001).
Squamous cell carcinoma antigen is a serine protease inhibitor
physiologically found in the spinous and granular layers of normal
squamous epithelium, but typically expressed by neoplastic cells of
epithelial origin (Kato, 1996). Recent studies indicate that both
SCCA1 and SCCA2, the two isoforms so far identified (Schneider
et al, 1995), protect neoplastic cells from apoptotic death induced
by several kinds of stimuli, and in vivo experiments demonstrate
that SCCA1 can promote tumour growth (Suminami et al, 2000,
2001). Little is known on the behaviour of this serpin in different
clinical settings; in particular, no information is available on its
expression in hepatocarcinoma. In the present study, we analysed
the expression of SCCA in a large series of HCCs of different
aetiology, using a novel antibody raised against SCCA variants and
cellular transcripts were then characterised by direct sequencing.
MATERIALS AND METHODS
Patients
The 65 HCC patients included in the study had a median age of 65
years (range 23–76 years), with a male/female ratio of 2:1. In total,
37 patients were anti-HCV positive, eight were HBsAg positive, six
were coinfected by HBV and HCV, eight admitted alcohol abuse,
while for the remaining six patients no risk factors were identified.
Liver function tests and AFP were available in all cases, as required
for clinical management of the patients. Liver specimens, achieved
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needle aspiration of hepatic nodules in 47 patients with cirrhosis,
while in the remaining 18 patients, including 12 cases with
cirrhosis and six without cirrhosis, specimens of tumour and
nontumour liver samples were collected at the time of surgical
resection. Formalin-fixed and paraffin-embedded sections were
available in all cases, while part of the surgical samples was snap
frozen in liquid nitrogen and stored at  801C for further analysis.
Control liver biopsies were obtained from 20 patients who
underwent cholecystectomy or liver biopsy for the staging of
mediastinal or laterocervical Hodgkin’s disease (Calabrese et al,
2000).
Histological evaluation
Paraffin sections were analysed for the presence of SCCA and
regeneration activity by immunohistochemistry. For SCCA detec-
tion, a novel polyclonal rabbit antibody (Hepa-Ab, Xeptagen, Italy)
raised against recombinant SCCA1 and affinity purified on a
Sepharose-SCCA1 column was used. Epitope mapping studies with
SCCA1 fragments obtained by SCCA1 enzymatic digestion or by
chemical synthesis indicated that the affinity-purified polyclonal
antibody recognises several epitopes located in the N-terminal, C-
terminal as well as in the central portion of SCCA1, as determined
by enzyme-linked immunosorbent assay (ELISA) and Western
blot. Hepa-Ab was used at a concentration of 4mgml
 1, while anti-
Ki67 (MIB-1, Immunotech, Marseille, France) monoclonal anti-
body was used at 1:50 dilution. Sections were incubated with
primary antibodies for 30min, after blocking endogenous
peroxidase activity with 3% hydrogen peroxide, heating the slides
in 10mM sodium citrate in a microwave oven and blocking
nonspecific protein binding in normal goat serum. Biotinylated
goat anti-rabbit or horse anti-mouse (Dako, Copenhagen, Den-
mark) was then added for 30min. Samples were incubated with
avidin–biotin–peroxidase and stained with a mixture of 3,30-
diamino-benzidine tetrahydrochloride (Dako) and hydrogen per-
oxide. For all experiments of immunohistochemistry, as negative
control, sections were incubated with the omission of primary
antibody, substituted by diluent or by the appropriate nonimmune
IgG in each case. Antibody specificity was confirmed using human
skin specimens for SCCA and colonic cancer specimens for Ki67,
as positive controls.
The percentage of stained cells in each specimen was scored on a
scale of 0–3, in which 0 denoted negative staining, score 1
positivity in 1–30% of hepatocytes, score 2 positivity in 31–50%
and score 3 in more than 50%. The distribution of immunor-
eactivity was noted and classified as diffuse, clustered or scattered.
In all cases, SCCA semiquantitative immunoreactivity was
independently evaluated by two pathologists, experts in the field.
Intra and interobserver differences were less than 5% and
discordant cases were re-evaluated simultaneously by two
observers.
For tumour liver specimens obtained by resection, MIB-1
immunostaining was randomly evaluated counting at least 1000
nuclei, while in liver samples obtained by needle aspiration all the
cells were counted (maximum 500 cells). The percentage of
positive nuclei was expressed as MIB-1 labelling index (MIB-1-LI).
In all immunohistochemical analysis, necrotic areas and edges
of tissue sections were not included in the counting to avoid
possible immunohistochemical false positivity.
Virological assessment
Anti-HCV antibody positivity was determined by commercially
available ELISA and confirmed by recombinant immunoblot assay
version 2 or 3 (Ortho Diagnostics, Raritan, NJ, USA). HBsAg,
HBeAg and the presence of serum anti-HBc, anti-HBe and anti-
HBs antibodies were evaluated by ELISA using commercially
available kits (Abbott Diagnostics, North Chicago, IL, USA). HCV
genotype was determined by the InnoLipa test (Innogenetics, Gent,
Belgium) after reverse transcription (RT)–PCR amplification. In
order to detect possible occult HBV infection, aliquots of liver
HBV DNA were assessed in 17 out of 18 HBsAg-negative surgical
samples by nested PCR using primers derived from the core and
the S regions of viral DNA (Cacciola et al, 1999).
Characterisation of SCCA transcripts
cDNAs of the SCCA-related variants were obtained by RT–
heminested PCR starting from total RNA extracted by single-step
guanidinium method (Chomczynsky and Sacchi, 1987) from
surgically obtained frozen tumour and nontumour liver samples.
Samples containing 1mg RNA were treated with 1Uml
 1 of DNAse
I in reaction buffer (200mM Tris-HCl (pH 8.4), 20mM MgCl2,
500mM HCl), followed by the addition of 25mM EDTA at 651C for
10min to block the reaction. To generate cDNAs of SCCA variants,
RT and amplification were carried out using primers located in
conserved regions of SCCA1 and SCCA2. Briefly, RT was carried
out using 2pmol of the antisense primer at position 1416–1386 of
SCCA sequence (Suminami et al, 1991) and 1ml of reverse
transcriptase (Superscript II, GIBCO BRL). For the first step of
cDNA amplification, 5Uml
 1 of Taq polymerase (Experteam,
Italy) and the following primers were used: sense (CAT GAA TTC
ACT CAG TGA AGC CAA C), antisense (GCA ATC AGT TTA CCA
GAA CAT CTG CAG). After 40 cycles at 941C for 1min, 601C for
30s, 721C for 1min, heminested PCR was carried out for additional
40 cycles in the same conditions using the sense primer described
above and the antisense primer (GAC TGA ATT CAA ATC CAC
TGA TGC). Actin mRNA was used as control of extracted RNA and
RT–PCR was assessed using the following primers: sense (GTG
GGG CGC CCC AGG CAC CA), antisense (CTC CTT AAT GTC
ACG CAC GAT TTC). cDNA amplification was carried out for 35
cycles at 941C for 1min, 551C for 1min and 721C for 2min.
Samples positive for the expected 945bp band obtained with the
SCCA-derived primers were directly sequenced in both strands
using an ABI PRISM BigDay terminator ready reaction kit
following the manufacturer’s instructions (Perkin Elmer Cetus,
Emeryville, CA, USA). Electrophoresis of the sequencing products
was performed by an ABI 377 automated DNA sequencer (Perkin
Elmer Cetus) according to the manufacturer.
Statistical analysis
The Kruskal–Wallis ANOVA median test, Spearman rank
correlation, w
2 and Fisher exact test were used for the analysis of
the results.
RESULTS
Immunohistochemistry
Squamous cell carcinoma antigen was detected by immunohis-
tochemistry in 55 out of 65 (85%) tumour specimens (18 out of 18
surgical specimens and 37 out of 47 fine-needle liver biopsies), but
in none of the 20 surgically obtained normal human livers
(Figure 1). In the majority of the cases, the positive signal was
clearly detectable with score 1 in 15% of the cases, score 2 in 29%
and score 3 in the remaining 56% of the patients. The same extent
of immunoreactivity was observed in liver tumours expressing
SCCA1, SCCA2 or SCCA-PD variants as detected by direct
sequencing (see below). In all cases, the serpin was detected in
the cell cytoplasm, with a prevalent diffuse pattern. In poorly
differentiated tumours, a typical clustered, coarse pattern was
observed (Figure 2). No correlation with the diameter, histotype or
grading of the tumour was observed. When surgical liver
specimens were considered, patients with cirrhosis showed a
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score7s.d.: 370.7 vs 270.4, Po0.05).
To correlate the presence of SCCA with liver regeneration
activity, consecutive slices of each tumour were stained with the
Ki-67 equivalent, MIB-1 antibody, which identifies cycling cells in
formalin-fixed tissue samples (Cattoretti et al, 1992).
Patients with SCCA score p1 showed values of MIB-1-LI
significantly lower than those obtained in patients with serpin
score X2 (meanþs.d.: 2%72.4 ([range 0.1 6.3%)] vs 7.5%710.3
([range 0.2 48%)], Po0.05), as shown in Figure 3.
Squamous cell carcinoma antigen transcripts analysis
Squamous cell carcinoma antigen mRNAs were detectable by
heminested PCR in 14 out of 18 tumour samples, generating a
single band at the expected size of 945bp. None of the
corresponding nontumour liver tissues showed detectable levels
of the serpin in the same experimental conditions (Figure 4A). The
sensitivity of this molecular approach was lower than that of
immunohistochemistry for SCCA, where all tumour samples were
positive for the serpin. The nucleotide sequence alignment of the
cDNA obtained by direct sequencing from the 14 tumours showed
that the major SCCA sequence had complete homology with
SCCA1 in six cases and with SCCA2 in three cases. In five
additional cases, a novel variant, presenting a G351 to A mutation,
in the reactive centre loop of the protein, was identified (Figure 4B)
and termed SCCA-PD (GenBank accession number: AY190327).
Correlation with clinical and virological parameters
The immunoreactivity for SCCA variants in liver tumours did not
show any relation with clinical and biochemical parameters,
including age, sex, transaminase or AFP levels. Aetiology of HCC
did not correlate with serpin expression, the mean7s.d. score
being 2.171.1 in HCV-infected patients, 2.171.7 in HBsAg-
positive patients, 2.270.4 in patients with HBV and HCV
coinfection, 2.171.6 in patients with alcohol abuse and 2.070.5
in cases without overt risk factors. Occult positivity for HBV was
detected in five out of 17 surgical samples obtained from HBsAg-
negative patients, independently of anti-HBc or anti-HBs positiv-
ity. In HCV-positive patients, no correlation with the infecting
genotype was observed.
DISCUSSION
In view of its prevalence and poor prognosis, HCC is a main
concern. This is the first report of an high expression of SCCA
in human liver cancer, detected in all surgical tumours and in 79%
of the samples obtained by fine-needle aspiration, confirming a
lower sensitivity of the single fine-needle procedure (Borzio et al,
1994). The majority of HCCs displayed the serpin at cytoplasmic
level, while its reactivity was not detectable in normal human
livers. The presence and extent of immunoreactivity, as detected
using a novel anti-SCCA antibody, was not correlated with
aetiologic risk factors, suggesting that overexpression of this
protein is involved in pathologic stages, beyond promotion of
cell transformation.
The role of serpins in neoplastic cells has been focused in several
studies and recent reports indicate that SCCA expression makes
cancer cells resistant to several killing mechanisms by inhibition of
apoptosis, involving caspase-3 activity and/or upstream proteases
(Suminami et al, 2000). So far, two isoforms of SCCA (SCCA1 and
SCCA2) deriving from two highly homologous tandemly arrayed
genes and their promoter regions have been identified on
chromosome 18q21.3 (Schneider et al, 1995; Sakaguchi et al,
1999; Hamada et al, 2001). In this study, direct sequencing was
used to characterise the expression of the major species of SCCA
variants in individual tumours and a new variant has been
identified in about one third of the cases, which is 99% identical to
SCCA1, but presents a G351 to A mutation in the reactive centre
of the protein. Since the mechanism of protease inhibition by
serpins involves a profound change in conformation, initiated by
Figure 1 Negative liver staining for SCCA variants by immunohisto-
chemistry in normal human liver (staging liver biopsy from a patient with
mediastinal Hodgkin’s disease). Original magnification:  20.
Figure 2 Immunohistochemistry for SCCA variants (score 3) in poorly
differentiated HCC (giant cell form): most of the tumour cells show typical
clustered, coarse, brown granules. Original magnification:  572.
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Figure 3 Proliferative activity expressed as MIB-1-labelling Index in
HCCs with different SCCA scores. Results are expressed as percent
meanþs.e. *Po0.05 vs score p1 group, Student’s paired t-test.
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(Huntington et al, 2000), the specific amino-acid change detected
in the reactive centre of SCCA-PD might confer a different
biological behaviour to the serpin and enzymatic activity of
this new variant is currently under investigation. Mutations
affecting this region may indeed result in inhibition of different
classes of proteinases, as shown for SCCA1 and SCCA2 (Kato,
1996) or in a loss or change of function, as described in several
human diseases affecting different members of the ovalbumin
family of serpins, including emphysema and cirrhosis, haemorra-
gic diseases, thrombosis and familial angioedema (Carrell and
Lomas, 2002).
The SCCA-PD variant was detected in one third of the cases and
the limited number of patients did not allow any correlation with
clinical or morphological parameters. Further studies are required
to assess whether tumour behaviour and clinical outcome of
patients with HCC are influenced by the extent and/or type of
SCCA expression in individual tumours.
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Patient 1 Patient 2  Patient 3 PC NC
330 340 350 360 370 380 390
SCCA1    LHKAFVEVTEEGAEAAAATAVVGFGSSPTSTNEEFHCNHPFLFFIRQNKTNSILFYGRFSSP
Case 1   ..............................................................
Case 3   ..............................................................
Case 10  ..............................................................
Case 11  ..............................................................
Case 12  ..............................................................
Case 13  ..............................................................
Case 2   ......................A.......................................
Case 5   ......................A.......................................
Case 6   ......................A.......................................
Case 7   ......................A.......................................
Case 14  ......................A.......................................
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Case 8   ............V.........VVEL.SP......C..........................
Case 9   ............V.........VVEL.SP......C..........................
SCCA2    ............V.........VVEL.SP......C..........................
945 bp
SCCA
 510 bp
   actin
A B
Figure 4 (A) Example of PCR amplification of SCCA cDNA by heminested PCR in tumour and nontumour liver tissue, surgically obtained from the same
patient. Parallel amplification of b actin cDNA is used as control of cellular mRNA. PC¼positive control; NC¼negative control. (B) Sequence alignment of
SCCA amino-acid sequences obtained from direct sequencing of cDNA of 14 HCCs. The sequence at the top is SCCA1 and the sequence at the bottom is
SCCA2 (Suminami et al, 1991). Amino-acid changes differing from SCCA1 reference sequence are reported. Cases 2, 5, 6, 7, 14 show the G351-A
mutation (SCCA-PD).
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